2Department of Agriculture, Jo.C, Islamic Azad University, Jouybar, Iran
35Arel University, Vocational School, Department of Electronics and Automation, Electronics Technology Program, Istanbul, Türkiye 6Mersin University, Institute of Science, Electrical and Electronic Engineering, Mersin, Türkiye
4Allergy and Asthma Center, Blue Area, Islamabad, Pakistan. Former Chief, Clinical and Tropical Diseases Research Division, National Institute of Health, Islamabad. Former HOD Allergy & Immunology, NIH, Islamabad, Pakistan
5Osmaniye Korkut Ata University, Bahce Vocational School, Management and Organization, Osmaniye, Türkiye
چکیده
Recent advances in molecular biology, nanotechnology, and immunology have been accountable for the advent of next-generation preventive and therapeutic methodologies. Prevention of infectious diseases is undergoing a revolution with updated and current molecular approaches, enabling faster, safer, and more effective alternatives to conventional vaccines and antivirals. This review work aimed to analyse the latest research on RNA therapeutics, nanovaccines, and immunomodulation, and highlights translational potential, implementation issues, and directions for the future in the context of a multidisciplinary, One Health-perspective approach to driving infectious disease prevention on a global scale. RNA therapeutics, including mRNA and self-amplifying RNA platforms, enable intracellular antigen expression, which leads to effective cellular and humoral immune responses with high ease to evolve against new pathogens. RNA therapies, nanovaccines, and immunomodulators permit antigenic control, targeted delivery of pathogens, and strong immune system activation. Nanovaccine platforms apply liposomes, polymeric nanoparticles, and virus-like particles to improve antigen stability, targeted delivery, and dose efficiency with oral and intranasal formulations for mass immunization and field deployment. Adjuvant immunomodulatory strategies, such as cytokine mimetics and TLR agonists, improve vaccine performance and induce protection against a broad range of pathogens. Integration with computational biology, omics, and systems immunology enables rational design, predictive modelling, and expediting preclinical development. The most recent developments in nanotechnology and molecular biology have transformed infectious disease prevention at its foundations. Nanovaccines, RNA therapeutics, and immunomodulation approaches offer targeted, scalable, and highly effective tools that improve immunogenicity, reduce doses of antigen, and allow rapid adaptation against emerging pathogens. The integration of AI with molecular approaches also offers paths for precision and personalized vaccinology. As a result, in line with the purpose of our review work, vaccines and treatments have been comprehensively evaluated in this context and scope, taking into account current approaches in the age of artificial intelligence.